Tags

Type your tag names separated by a space and hit enter

Hemostatic laboratory derangements in COVID-19 with a focus on platelet count.
Platelets. 2020 Aug 17; 31(6):740-745.P

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease in 2019 (COVID-19) which rapidly evolved from an outbreak in Wuhan, China into a pandemic that has resulted in over millions of infections and over hundreds of thousands of mortalities worldwide. Various coagulopathies have been reported in association with COVID-19, including disseminated intravascular coagulation (DIC), sepsis-induced coagulopathy (SIC), local microthrombi, venous thromboembolism (VTE), arterial thrombotic complications, and thrombo-inflammation. There is a plethora of publications and conflicting data on hematological and hemostatic derangements in COVID-19 with some data suggesting the link to disease progress, severity and/or mortality. There is also growing evidence of potentially useful clinical biomarkers to predict COVID-19 progression and disease outcomes. Of those, a link between thrombocytopenia and COVID-19 severity or mortality was suggested. In this opinion report, we examine the published evidence of hematological and hemostatic laboratory derangements in COVID-19 and the interrelated SARS-CoV-2 induced inflammation, with a focussed discussion on platelet count alterations. We explore whether thrombocytopenia could be a potential disease biomarker and we provide recommendations for future studies in this regard.

Authors+Show Affiliations

School of Medicine, Georgetown University , Washington, DC, USA.Department of Biomedical and Molecular Sciences, School of Medicine, Queen's University , Kingston, Canada. School of Baccalaureate Nursing, St. Lawrence College , Kingston, Canada.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32456506

Citation

Amgalan, Ariunzaya, and Maha Othman. "Hemostatic Laboratory Derangements in COVID-19 With a Focus On Platelet Count." Platelets, vol. 31, no. 6, 2020, pp. 740-745.
Amgalan A, Othman M. Hemostatic laboratory derangements in COVID-19 with a focus on platelet count. Platelets. 2020;31(6):740-745.
Amgalan, A., & Othman, M. (2020). Hemostatic laboratory derangements in COVID-19 with a focus on platelet count. Platelets, 31(6), 740-745. https://doi.org/10.1080/09537104.2020.1768523
Amgalan A, Othman M. Hemostatic Laboratory Derangements in COVID-19 With a Focus On Platelet Count. Platelets. 2020 Aug 17;31(6):740-745. PubMed PMID: 32456506.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Hemostatic laboratory derangements in COVID-19 with a focus on platelet count. AU - Amgalan,Ariunzaya, AU - Othman,Maha, Y1 - 2020/05/26/ PY - 2020/5/28/pubmed PY - 2020/8/22/medline PY - 2020/5/28/entrez KW - COVID KW - SARS-CoV-2 KW - platelets KW - thrombocytopenia KW - thromboinflammation SP - 740 EP - 745 JF - Platelets JO - Platelets VL - 31 IS - 6 N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease in 2019 (COVID-19) which rapidly evolved from an outbreak in Wuhan, China into a pandemic that has resulted in over millions of infections and over hundreds of thousands of mortalities worldwide. Various coagulopathies have been reported in association with COVID-19, including disseminated intravascular coagulation (DIC), sepsis-induced coagulopathy (SIC), local microthrombi, venous thromboembolism (VTE), arterial thrombotic complications, and thrombo-inflammation. There is a plethora of publications and conflicting data on hematological and hemostatic derangements in COVID-19 with some data suggesting the link to disease progress, severity and/or mortality. There is also growing evidence of potentially useful clinical biomarkers to predict COVID-19 progression and disease outcomes. Of those, a link between thrombocytopenia and COVID-19 severity or mortality was suggested. In this opinion report, we examine the published evidence of hematological and hemostatic laboratory derangements in COVID-19 and the interrelated SARS-CoV-2 induced inflammation, with a focussed discussion on platelet count alterations. We explore whether thrombocytopenia could be a potential disease biomarker and we provide recommendations for future studies in this regard. SN - 1369-1635 UR - https://www.unboundmedicine.com/medline/citation/32456506/Hemostatic_laboratory_derangements_in_COVID_19_with_a_focus_on_platelet_count_ L2 - https://www.tandfonline.com/doi/full/10.1080/09537104.2020.1768523 DB - PRIME DP - Unbound Medicine ER -